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ABSTRACT: The aim ofthis study was to observe responses of  
serum antioxidants, oxidative stress biomarkers, and macular 
carotenoid pigments to antioxidant supplements or dietary 
intervention in a single-masked, randomized, pilot clinical study 
of elderly subjects receiving an tioxidan t  supplements or a dietary 
intervention. Methods: From a pool o f ninety-eight community 
volunteers, forty-eight male and female subjects (age65-85) with 
the lowest baseline serum lutein + zeaxanthin levels were selected 
and randomly assigned to receive for 12 weeks one o f two 
different antioxidant supplements or a diet rich in fruits and 
vegetables containing approximately matched levels o f four classes 
of carotenoids: carotenes, the xanthophylls lutein and zeaxanthin, 
and lycopene. Forty-six completed the study. Both supplements 
and diet also were rich in vitamins C and E. Outcome measures 
were changes from baseline: 1) in serum levels o f  antioxidant 
micronutrients (vitamins C and E, lutein, zeaxanthin, and 
P carotenej; 2) in levels o f  indicators o f  oxidative stress: serum 
lipid peroxides (LPO) and urinary 8-hydroxydeoxyguanosine 
(8-O H dG ); and 3 ) m acular pigm ent, m easured by 
heterochromatic flicker photometry. Results: Interventions to 
promote eye health by either diet or supplementation shoived 
consistent serum responses, with substantial improvements 
within tivelve weeks. Serum lutein and vitamin C increased for 
all groups (p< 0.05), and lipid peroxides decreasedfor all subjects 
(p< 0.05); nonetheless, mean macular pigment d id  not increase 
significantly during the designated timeframe. Conclusion: 
Supplementation o f  elderly individuals potentially a t risk for 
AMD with two different types o f antioxidant formulations 
exhibited positive serum responses sim ilar to a dietary  
intervention containing approximately comparable levels o f  
carotenoids. Thispilot study indicates that the ocular supplements 
tested in this study elicited responses in serum parameters sim ilar 
to daily consumption o f four servings o f  carotenoid-rich fruits 
and vegetables. The study also provides useful criteria for the 
design o f larger-scale and longer-term studies o f  antioxidant 
supplementation in an elderly population potentially at riskfor 
AMD.
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause 
of blindness in adults over the age of 65 in developed nations 
(Age-related Eye Disease Study (AREDS), 2001; Klaver et al., 
1998). Treatments for AMD, especially for the “wet” or exudative 
form, have improved dramatically in recent years, but a large 
percentage of AMD patients still end up with severe visual loss. 
Therefore, much research has focused on prevention through 
identification of modifiable risk factors, such as diet, smoking, 
and light exposure. Among dietary risk factors, antioxidant status 
has been inversely correlated with risk for advanced AMD and 
age-related cataracts (AREDS, 2001; Klaver etal., 1998; Seddon 
et al., 1994; Delcourt et al., 1999; and Gale et al., 2001), although 
not all researchers have confirmed this relationship (Mares-Perlman 
et al., 1995; Smith et al., 1999; and Taylor et al., 2002).
In order to resolve these disparities, the National Eye Institute 
(NEI) organized a large-scale, prospective, clinical trial conducted 
by the Age-Related Eye Disease Study (AREDS) group to 
determine the effects of antioxidant intervention on the 
progression of AMD (AREDS, 2001). The trial established that 
individuals in the two most advanced AMD categories 
supplemented with a combination of zinc and antioxidants had 
an approximately 25% reduction in risk for progressing to 
advanced AMD (AREDS, 2001). The trial, however, did not 
address all of the dietary antioxidants that may affect macular 
health. The xanthophyll carotenoids lutein (L) and zeaxanthin 
(Z), found in dark green leafy vegetables, and orange or yellow 
fruits and vegetables, have been linked epidemiologically and 
anecdotally with a decreased risk for AMD (AREDS, 2001; 
Seddon et al., 1994; Moeller et al., 2000; Mares-Perlman et al., 
1999; Schlach et al., 1999; Snodderly et al., 1995; Landrum et
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al., 2001; and Schlach et al., 2002). Lutein and zeaxanthin are 
selectively concentrated in the macula where their capacity, 
observed in vitro, to filter blue light (Junghans, et al., 2001) and 
remove reactive oxygen species (Sujak et al., 1999) is believed to 
protect sensitive retinal tissues.
Research has shown that levels of macular pigment can be 
increased gradually in responders when lutein intake is increased 
in young healthy individuals, either via a nutritional supplement 
(Landrum et al., 1997; Berendschot et al., 2000) or increased 
consumption of foods high in lutein (Hammond et al., 1997). 
Comparatively little research has been done to assess the 
physiological effects of supplementation in the elderly with lutein 
alone or in combination with other antioxidant vitamins and 
minerals, although several recent investigations have provided 
support for the epidemiological projections (Bone et al., 2003; 
Nelson et al., 2003; Richer et al., 2004), and a recent review 
summarizes the current understanding (Bernstein et al., 2003).
Given the likely importance of xanthophylls in maintaining 
macular health, it would be helpful to investigate them in a 
manner similar to the AREDS trial. Before such a trial should be 
undertaken, however, an adequate dose of lutein, the approximate 
timeframe for tissue response, as well as the appropriate mixture 
and chemical forms of supplementary antioxidants, need to be 
evaluated to determine bioavailability since nutrients that act in 
one manner when given alone, may act differently when ingested 
with other nutrients (Groff et al., 1999). Also, it is important to 
monitor tissue response to lutein supplementation in the macula 
noninvasively during a clinical trial 
because serum  response to 
supplementation does not always 
correlate well with macular levels 
(Landrum et al., 1997; Berendschot 
etal., 2000; Hammond etal., 1997).
We compared the efficacy in an elderly 
population of two dosage forms of 
ocular an tiox idant supplem ents 
containing different amounts of lutein 
and zeaxanthin and varying 
complements of alternate antioxidant 
micronutrients, relative to a dietary 
intervention rich in carotenoids from 
four daily servings of fruits and 
vegetables. The evaluated responses 
included serum carotenoid levels, 
macular pigment density, antioxidant 
micronutrients, and biomarkers of 
oxidative stress. Since supplements 
offer a low-risk source of antioxidants 
-  free of contamination from heavy 
metals, organics, pesticides and 
bacterial load -  the question to be 
resolved was whether the particular 
matrix (vegetables themselves, dosage 
form , or supplem ent source) 
influenced the n u tritio n a l and 
prophylactic value for an elderly 
population.
METHODS
This study was a single-masked randomly assigned, clinical 
trial of the responses of serum and macular pigment to dietary 
supplementation. Initial values of each group served as its own 
control. We tested two prototype antioxidant supplements 
formulated to promote eye health but differing in composition, 
stability, and bioavailability (Table 1). Our control group did not 
take supplements but consumed a diet rich in carotenoid- 
containing fruits and vegetables. Although, a fourth group 
receiving only a placebo or no intervention would have been 
ideal, we found in a previous study (Nelson et al., 2003) that the 
presence of such a group proved to be a severe barrier to subject 
recruitment, so it was omitted. The three groups were assigned 
the following regimens: 1) a supplement capsule at two per day 
(Capsule group; m anufactured by N atural Alternatives 
International, San Marcos, CA); 2) a supplement tablet at two 
per day (Tablet group; manufactured by J. B. Laboratories, 
Holland, MT); and 3) a dietary intervention designed to provide 
levels of carotenoids ((3-carotene, xanthophylls, and lycopene) 
similar to those provided by the supplements (Diet group). Lutein 
and zeaxanthin in the supplements were derived primarily from 
marigolds and provided as beadlets of free alcohol (FloraGlo® 
Lutein, Kemin Health, Des Moines, IA). Monitored responses 
included serum and urine levels of oxidative stress, serum levels of 
antioxidants including carotenoids, vitamins C and E, and macular 
pigment.
Table 1. Supplement Content for Capsule and Tablet Formulations*
Units Supplement Capsule
per capsule per day
Supplement Tablet
per tablet per day
Lutein and Zeaxanthin1 mg 2
P- Carotene IU 2,000 4,000 3,300 6,600
Lycopene mg 0.25 0.50
Vitamin C (ascorbic acid) mg 45 90 200 400
Vitamin E (a-tocopherol) IU 75 150
Vitamin B-l (thiamin) mg 1.125 2.25
Vitamin B-2 (riboflavin) mg 1.3 2.6 10
Vitamin B-3 (niacinamide) mg 10 20
Vitamin B-6 (pyridoxine) mg 1.5
Vitamin B-l2 mg 0.0005 0.001
Folic Acid mg 0.1 0.2
Biotin mg 0.075 0.15
Pantothenic Acid mg 7.5 15
Zinc acetate mg 30 60
Copper mg
Manganese mg 10
Selenium mg 0.025 0.050 0.02 0.04
Grape Seed Extract mg 10
Spinach Leaf Powder mg 50 100
Green Tea Extract mg 50 100
Bilberry extract mg 20 40
Blueberry Fruit Powder mg 25 50
Lemon Powder mg 125 250
Peach fruit powder mg 20 40
’ Contains 95 ± 2 % lutein and 5 ± 2 % zeaxanthin according to the manufacturers specifications. 
2 Supplies approximately 30 micrograms of lutein per capsule.
* Subjects in the diet group consumed approximately 6 mg lutein, 0.6 mg zeaxanthin, 10 mg 
lycopene, and 8 mg of (3-carotene for 5 of 7 days per week.
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Sample size
The number of study subjects needed to obtain significance 
was determined using a power analysis (SPSS, 2.03 ed.) with a 
projected difference of 40% in serum responses for plasma lutein, 
zeaxanthin, and lipid peroxides (LPO) from baseline, an alpha of 
0.05, and a power of 0.80. The analyses were performed on 
reference means and standard deviations for a population of 
individuals over the age of 65 and were based on existing literature 
data for the second most important key indicator, serum lutein 
levels, since not enough data existed to utilize the most critical 
indicator, the level of carotenoids in the macula. Fifteen test 
subjects per group were determined to be sufficient to detect a 
40% change in serum lutein levels from baseline.
Sample selection
Our intent was to select for the saidy individuals potentially at 
risk for macular degeneration based upon serum carotenoid levels. 
Ninety-eight volunteers were recruited from a local geriatric 
population (ages 65-85). These subjects were recruited using 
advertisements, flyers, a Moran F.ye Center volunteer database, 
and word of mouth. Subjects’ fasting blood samples were 
prescreened for serum lutein and zeaxanthin levels. Prescreening 
assays were performed by an outside reference laboratory (Genox, 
Baltimore, MD). The 48 subjects with the lowest combined 
serum levels o f lutein and zeaxanthin (L + Z) were selected for 
the full 12-week study. The study was approved by the 
University of Utah Institutional Review Board (IRB #8752­
01), and informed consent was obtained from each subject.
F.xclusion criteria  included subjects con tinu ing  on 
supplements, cholesterol-lowering medications that affect lipid 
metabolism (e.g., Cholestyramine), or lipid-binding medications 
(e.g., Orlistat). Subjects who were taking 3-hydroxy-3- 
methylglutaryl (HMG)-CoA reductase inhibitors, such as Lipitor, 
were not excluded from the study. People with renal disease were 
excluded. Subjects on medications were required to be stable for 
at least 5 weeks prior to the study. Subjects were allowed to take 
calcium and other non-antioxidant supplements. Subjects with 
poor pupillary dilation or with significant cataracts, exudative 
AMD, geographic atrophy, or diabetic macular edema, were also 
excluded.
Data Acquisition
Following overnight fasting, 10 ml of antecubital venous blood 
was withdrawn from each of the 98 volunteers. The blood was 
collected in serum-separator tubes, refrigerated, and centrifuged 
at 1500 x g for 15 minutes. Serum was pipetted in 1.5 mL 
aliquots into four cryotubes and stored frozen at ^80°C until 
they were shipped to reference laboratories on dry ice for analysis.
Serum samples were analyzed for lutein (L) and zeaxanthin 
(Z) concentrations. Forty-eight subjects with the lowest combined 
L + Z levels, the fraction of the population presumed to be at 
greatest risk, were selected for the full 12-week study since current 
methodology used to assess macular pigment levels does not 
differentiate between L and Z.
The selected subjects were randomly assigned to three different 
groups using a computerized randomization program, and then
each group was randomly assigned to receive either one of two 
ocular antioxidant formulations or to take part in the dietary 
intervention. The supplements differed with respect to the 
number of antioxidants, the amounts of antioxidants, the 
amounts of lutein and zeaxanthin, and the number of other 
excipients that may have been added (Table 1). The dietary 
intervention was designed to provide levels of lutein and 
zeaxanthin comparable to the supplements, 25-30 mg of total 
carotenoids per day. Patients selected daily from each of four 
categories of carotenoid, and thereby approximated the amounts 
of (3-carotene, lutein and zeaxanthin received from the 
supplements. Selections from Category 1 (green fruits and 
vegetables) provided an average of 6 mg of lutein and 0.2 mg of 
zeaxanthin, from Category 2 (red fruits and vegetables) an average 
of at least 10 mg of lycopene, from Category 3 (yellow fruits and 
vegetables) an average of 0.4 mg of zeaxanthin, and from Category 
4 (orange fruits and vegetables) an average of 8 mg of (3-carotene 
per serving.
After a 2-week washout period, subjects brought a 24-hour 
urine collection to the Moran F.ye Center. The urine samples 
were pipetted into 4 different 1 mL cryotubes and frozen at - 
80°C until they were shipped for analysis. Genox Laboratories 
(Baltimore, MD) analyzed serum and urine samples. Subjects 
had their visual acuity checked and received a dilated eye exam 
from an ophthalmologist. Subjects also had their macular pigment 
measured via heterochromatic flicker photometry (HFP) if their 
visual acuity was at least 20/50.
Subjects then received 12-weeks worth of pills if they were in 
a supplement group. Subjects were instructed to take the pills 
twice daily with food to maximize absorption. Notebooks were 
provided so that subjects could keep track of when they took 
their pills. If one pill was missed, subjects were instructed to take 
two pills the next time. If an entire day’s worth of pills were 
missed, subjects were instructed to skip them and continue as 
normal from that point on. They were also instructed to record 
any fruits or vegetables that they ate for the entire study in these 
notebooks. All subjects kept detailed 3-day food records 
immediately prior to and after completing the study to ascertain 
what foods they were habitually eating and to confirm that there 
were no major changes in dietary habits over the course of the 
study beyond the fruit and vegetable intervention.
Due to the long duration of the study, subjects in the diet 
group were asked to eat fruits and vegetables from the lists only 5 
of the 7 days per week. They were also given notebooks to record 
their participation in the study, and were instructed to record 
which foods they chose from the lists, how they were prepared, 
how much they ate and which days they were “off diet.” Subjects 
were also asked to record any other fruits or vegetables they ate 
during this time. Subjects received phone calls every 3 weeks 
during the study to encourage compliance and to check for any 
problems.
At the end of the 12 weeks, subjects returned to the Moran 
Eye Center. They brought another 24-hour urine collection and 
again had blood drawn. They also turned in their notebooks of 
food intake records at this time. Subjects had their macular 
pigment measured again by HFP.
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Sample analysis
Serum was analyzed by the reference laboratory (Genox, 
Baltimore, MD) for lutein, zeaxanthin, a? and P-carotene, 
P'Cryptoxanthin, lycopene, a? and y-tocopherol, vitamin C, and 
LPO. Urine was analyzed for creatinine and 8-OHdG. The 
hydrophobic carotenoids and tocopherols were measured together. 
One-hundred mL of serum were taken from each sample. Proteins 
in the serum were denatured with ethanol. The carotenoids and 
tocopherols were extracted with hexane and analyzed by reverse- 
phase HPLC with an isocratic mobile phase. A photodiode array 
was used to measure carotenoids, and tocopherols were detected 
with fluorescence (Hammond et al., 1997; Clinton et al., 1996; 
Dorgan et al., 1998; Khachik et al., 1995; Murakashi et al., 
1992).
Vitamin C and urine creatinine were analyzed using a 
spectrophotometric assay performed on a robotic chemical analyzer 
(McGown et al, 1982;Bowers et al„ 1980).
Urine samples were clarified if necessary by centrifuging urine 
at 2,000 x g for 10 minutes (for opaque samples only; clear 
samples were not centrifuged) prior to analysis for 8-OHdG. A 
primary 8-OHdG monoclonal antibody was added to a solution 
composed of either sample or standard. That solution was added 
to a microtiter plate to which 8-OHdG had been bound. The 
primary antibody bound competitively to either 8-OHdG in 
solution or to 8-OHdG bound to a microtiter plate. Higher 
concentrations of 8-OHdG in solution led to reduced binding of 
the primary antibody to the 8-OHdG on the plate. The amount 
of bound primary antibody was quantified colorimetrically by 
reacting it with a secondary antibody that could be activated 
with a reagent. The kit is available commercially (8-OHdG ELISA 
Kit GC, Genox laboratories Baltimore, Maryland 21230).
Lipid hydroperoxides (LPO) were analyzed at Genox using a 
commercial test kit. Briefly, in the presence of hemoglobin, lipid 
hydroperoxides were reduced to hydroxyl derivatives (lipid 
alcohols) and the 1 0-iV -m ethylcarbam oyl-3,7-bis 
(dimethylamino)phenothiazine (M CDP) chromogen was 
oxidatively cleaved to form methylene blue in an equal 
molar reaction. Lipid peroxides were quantitated 
colorimetrically by measuring the methylene blue at 675 nm.
Macular Pigment Measurements
Snodderly et al. have described the Heterochromatic 
Flicker Photometry (HFP) psychophysical method of 
measuring macular pigment at considerable length 
(Snodderly et al., 1999). Briefly, a stimulus of short- 
wavelength light close to the absorbance peak of macular 
pigment (460 nm) is alternated with middle-wavelength 
light (560 nm), which is not absorbed by the macular 
pigment. The flickering stimulus is focused on the foveal 
center where macular pigment reaches its maximum 
concentration, and then to the parafovea where macular 
pigment is at a very low level. The subject can adjust the 
relative luminance of one light source, eliminating the 
flicker. The difference between the foveal and parafoveal 
sensitivities to blue light is used as a measurement of 
macular pigment density (Snodderly etal., 1999). HFP
can yield reproducible results and show good retest reliability 
(Snodderly et al., 1999). However, some subjects find the task of 
HFP difficult to perform, particularly those with poor visual acuity 
(Snodderly et al„ 1999; Curran-Celantano et al, 2002). The 
instrument used in these studies was a Bone and Landrum flicker 
photometer, model number FPM302’. The foveal spot size was
1.5° with a flicker rate of 32 Hz, and the peripheral reference 
point was at 7° with a flicker rate of 1 5 Hz.
Statistical Analysis
Data were analyzed using SPSS for Windows, version 10.0 
(SPSS, Chicago, IL). Parametric statistical tests were used to analyze 
these data. Power analyses were conducted using Sigma Stat for 
Windows, version 2.03. A paired t-test was used to determine 
changes from baseline within groups, and an analysis of covariance 
(ANCOVA) was used to assess the significance of differences 
between groups, with pre-test scores put in as the covariate (Green 
et al., 2000). A two-way ANCOVA was used to determine 
differences between groups for males and females and for those 
with AMD and those without, with the pre-test scores put in as 
a covariate (Green et al., 2000). Alpha was adjusted using Holm’s 
Sequential Bonferroni Procedure to correct for multiple 
comparisons of the data (Green et al., 2000). Pearson’s r test was 
used to assess relationships between variables (Green et al., 2000).
RESULTS
Subject Characteristics
Information from the selected 48 subjects was initially collected 
with respect to age, gender, incidence of eye disease, incidence of 
diabetes, height, weight, body mass index (BMI), percent body 
fat measured by a bioelectric impedance analyzer (Tanita 
Corporation, Arlington Heights, IL), smoking behavior, and iris 
color. Table 2 compares the characteristics of the individuals 
participating in the three treatment groups. The Diet group was 
significantly heavier and had a higher BMI. There were no other 
statistically significant imbalances between the groups.
Table 2. Subject Characteristics
Capsule(n = 16) Tablet(n = 16) Diet (n = 16)
Males 7 10 7
Females 6
Age (Mean ± SD) 70.7 ± 5.4 72.5 ±4.1 71.1 ± 5.6






Patients with AMD (dry, wet) 4 (4, 0) 3 (1, 2) 3 (3, 0)
Patients with diabetes 1 2
Pseudophakic patients 4 4
Height (cm) 172.5 ± 10.1 174.0 ± 10.9 175.0 ±7.1
Weight (kg) 80.4 ± 13.6 80.6 ± 16.4 89.0 ± 16.91
Body Mass Index (BMI) 26.9 ± 3.4 26.8 ±4.1 29.1 ± 5.11
Percent body fat 33.2 ± 9.2 30.8 ± 8.5 34.7 ± 11.7
Diet group participants significantly different than the other two groups, p< 0.01.
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O f the 48 subjects selected for the study of the two supplements 
and the carotenoid-rich diet, 46 (96%) completed the full 12- 
week intervention. One subject (assigned to the Tablet group) 
suffered a progression in his pre-existing AMD within the first 
few weeks, and he decided to seek medical attention rather than 
continue participation in the study. The other subject (assigned 
to the Diet group) suffered a fall and broke her humerus, and she 
was unable to complete study procedures.
Compliance with the interventions, as measured by the 
individuals’ records of consumption and serum carotenoid 
responses, was high for all treatments. Both supplement groups 
reported an average of 95% compliance with the tablet or capsule 
regimens. The compliance for the diet group amongst the four 
categories was high: 94% in the green category, 119% in the red, 
96% in the yellow, and 103% compliance in the orange category. 
(Percentages greater than 100% indicate that the subjects 
consumed more than the required amounts of fruits and 
vegetables.)
The Diet group consumed significantly more servings of fruits 
and vegetables than the other subjects, 4.8 servings per day, 
compared to 2.8 servings per day (p < 0.001). However, the Diet 
group consumed less total L + Z on average per day (2.5 mg) than 
the supplement groups when supplement amounts were included 
along with their dietary intakes as determined from the food 
intake diaries (Capsule = 6.9 mg/d. Tablet = 4.9 mg/d) (p < 
0.01). While the Diet group exhibited excellent compliance.
their daily selections of foods containing L + Z did not achieve 
the goal of 6 mg/d.
Serum carotenoids
The mean serum levels and standard deviations for carotenoids 
pre- and post- intervention for all groups are listed in Table 3. 
Serum lutein levels were increased for all groups, regardless of the 
intervention (p <0.05) with a somewhat greater response observed 
in the Tablet group; however, zeaxanthin levels were not 
significantly increased for any group. Combined lutein and 
zeaxanthin (L + Z) levels did not increase significantly pre to post 
for any group, but were significantly increased (p< 0.05) when 
all subjects were combined (Total). The Tablet group doubled its 
(3-carotene level in response to supplementation, while responses 
were more modest in the other two groups. Only the Diet group 
exhibited significant elevations in lycopene and in (3-cryptoxanthin.
Antioxidant vitamins
The effects of the interventions with vitamin C and the 
tocopherols also are listed in Table 3. All groups had a significant 
increase in serum vitamin C levels. This was observed both within 
groups (p< 0.01) and for all subjects (p< 0.01). Only the Tablet 
group showed any significant increases in a-tocopherol (p< 0.01). 
The Tablet group was also the only group to show a significant 
decrease in y-tocopherol levels (p< 0.05).

















(Mean ± SD) 
Pre- Post-
Lutein (I,) 0.11 ±0.04 0.16 ±0.08' 0.11 ±0.04 0.22 ±0.13' 0.12 ±0.03 0.16±0.161 0.11 ±0.04 0.18 ± 0.101
Zeaxanthin (Z) 0.04 ±0.02 0.03 ±0.01 0.04 ±0.01 0.04 ±0.02 0.05 ±0.02 0.04 ±0.02 0.05 ±0.02 0.04 ±0.02
L + Z 0.15 ±0.05 0.19± 0.10 0.16 ±0.05 0.26 ±0.14 0.17 ±0.05 0.20 ±0.08 0.16 ±0.05 0.22 ± 0.111
Lycopene 0.13 ±0.07 0.10 ±0.06 0.15 ± 0.11 0.15 ±0.08 0.14 ±0.06 0.18 ± 0.07u 0.14 ±0.08 0.14 ±0.08
(X-Carotene 0.07 ± .05 0.09 ±0.07 0.09 ± 0.09 0.11 ±0.08 0.14 ± 0.18 0.19 ± 0.16 0.10 ± 0.12 0.13 ±0.12'
(3-Carotene 0.20 ±0.11 0.26 ±0.11 0.30 ±0.20 0.62 ± 0.531,2 0.29 ±0.20 0.34 ±0.19 0.26 ±0.19 0.40 ±0.36'
(3-Cryptoxanthin 0.06 ±0.04 0.06 ±0.03 0.07 ±0.06 0.07 ±0.05 0.06 ±0.03 0.12 ± 0.061'4 0.06 ±0.04 0.08 ±0.05*
Vitamin C 8.13 ± 1.1 9.10 ±0.97' 8.32 ±1.2 9.92 ± 1.6U 7.99 ±0.61 8.83 ± 0.651 8.15 ± 0.10 9.28 ±0.12'
OC-Tocopherol 12.5 ±4.7 10.8 ±2.2 13.6 ±7.1 16.6±7.6U 11.5 ±2.5 10.4 ± 1.9 12.5 ±5.1 12.6 ±5.3
y-Tocopherol 1.49 ±0.93 1.33 ±0.55 1.53 ±0.53 1.12±.471 1.45 ±0.58 1.45 ±0.55 1.49 ±0.69 1.30 ±0.53
1 Indicates a significant difference between Pre- and Post- values, p< 0.05.
2 Indicates a significant difference between Tablet and the other two groups, p< 0.05.
3 Indicates a significant difference between Diet and Capsule, p< 0.01.
1 Indicates a significant difference between Diet and the other two groups, p< 0.01.
Table 4. Levels o f  Oxidative Stress Biomarkers Pre- and Post- Intervention
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Capsule (n = 16)
(Mean ± SD)
Pre- Post-
Tablet (n = 15)
(Mean ± SD)
Pre- Post-
Diet (n = 15)
(Mean ± SD) 
Pre- Post-






0.14 ±0.07  0.14 ± 0.08 
1.42 ± 0.24 1.29 ±0.25*
0.13 ±0.08 0.11 ±0.09 
1.31 ± 0.45 1.25 ±0.35
0.14 ±0.10 0.13 ±0.10 
1.33 ± 0.44 1.22 ±0.36
0.14 ±0.08 0.13 ±0.09 
1.40 ± 0.38 1.25 ±0.32*
1 Indicates a significant difference between Pre- and Post- values, p< 0.05.
Abbreviations: 8-hydroxydeoxyguanosine (8-OHdG); lipid peroxides (LPO); CRF. (creatinine).
Oxidative stress indicators
The effects of the various treatments on urinary 8-OHdG and 
serum LPO, both indicators of oxidative stress are listed in Table
4. No significant change in 8-OHdG was observed for any 
group or the total population. A significant decrease in LPO was 
observed for all subjects combined (p< 0.05); however, only the 
Capsule group showed a significant decrease within the group 
(p< 0.05).
Macular pigment levels
No discernible differences in macular pigment were observed 
from pre- to post- intervention for any group (Table 5). No other 
significant differences were found when the data were examined 
by gender or by a person’s AMD status. Tn part, this was a 
consequence of the limited number of subjects capable of 
performing the measurements reproducibly.
DISCUSSION
Based on epidemiology, it has long been suspected that AMD 
is in part a disease of oxidative stress, and recent research has 
supported that linkage (Bernstein et al., 2001; Beatty et al., 2000). 
The AREDS study is the first large clinical intervention to provide 
compelling evidence for recom m ending antioxidants-a 
combination of zinc, copper, vitamin C, vitamin E, and p-carotene- as 
the standard of care for patients at high-risk for progression to 
advanced AMD (AREDS, 2001), but it certainly is not the last 
study to explore nutrients capable of delaying progression of 
AMD. Other antioxidants need to be tested, and formulations 
need to be optimized to improve the success of nutritional 
interventions. Smaller pilot studies can serve to assist in the 
identification of ingredients and their amounts that may be 
capable of improving efficacy of the original AREDS composition, 
and identifying surrogate noninvasive and minimally invasive 
biomarkers indicative of a protective response to antioxidant 
interventions. These pilot studies can provide guidance for the 
design of the next generation of large-scale interventional trials 
against AMD.
Tn this pilot study the responses recorded changes observed in 
a 12-week period of supplementation in an elderly population. 
The main outcome measures were serum increases in carotenoids
and antioxidant vitamins and alterations in serum and urinary 
biomarkers of oxidative stress (LPO and 8-OHdG). All three 
interventions contained considerably more than the 2 mg/day 
consumption of lutein and zeaxanthin that might be predicted 
for an elderly population based upon NHANES TTT intake data. 
These amounts were anticipated to increase macular pigment 
levels, which were monitored noninvasively by heterochromatic 
flicker photometry.
All three groups reported excellent compliance with the study 
regimens, and this was mirrored by the positive serum response 
for many of the nutrients. Serum lutein levels rose in a significant 
manner in the range of 50-100% in all groups in response to a 
substantial increase in lutein intake relative to the usual American 
dietary intake. Although the capsule formulation contained more 
lutein and zeaxanthin than the tablet formulation, the serum 
level increased more for individuals consuming the tablet 
formulation. One inference could be that the slower release of 
nutrients from the tablet improved bioavailability, and that the 
type of formulation can influence absorption.
Likewise, p-carotene levels rose in all groups, especially in the 
Tablet group. Lycopene and p-cryptoxanthin were elevated in 
the Diet group only, as anticipated since these components were 
not provided in either the tablet or capsule supplement but were 
present in the dietary food selection categories. Serum zeaxanthin 
levels were largely unchanged in all three groups, as expected, 
since the supplements and the diet provided 0.6 mg or less of this 
nutrient.
Vitamin C levels also rose significantly for all groups, especially 
when the Tablet formulation was employed. Vitamin E response 
was less consistent, however. Only the Tablet group showed a 
significant increase in serum a-tocopherol, with a small but 
significant decline in y-tocopherol. This decline may have resulted 
from the documented competition of a -  and y-tocopherol for 
specific binding sites on endogenous binding proteins 
(Handelman et al., 1985, Hosomi et al., 1997).
Accompanying increases in serum antioxidants, a reduction in 
two biomarkers of oxidative stress, serum LPO and urinary 
8-OHdG, was anticipated. All three groups demonstrated a trend 
for decreased LPO, and these trends were significant for the 
Capsule group and for the pooled populations. 8-OHdG levels
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were unchanged or slightly decreased but never reached statistical 
significance. These trends suggest one or both of these oxidative 
stress biomarkers may be useful to incorporate into larger clinical 
trials of antioxidant supplements in AMD populations. There is 
some evidence to suggest that the effects of oxidative stress as 
measured by 8-OHdG may not decrease significantly as a result 
of antioxidant intervention unless the subjects are experiencing 
high levels of pre-existing oxidative stress (Schmidt et al., 2000). 
Our subjects were generally healthy and free of known oxidative 
stress such as smoking or renal failure. This work suggests that 
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these results may be that eighty-eight of the ninety-eight original 
volunteers reported regular use of a variety of supplements 
containing a variety of antioxidants prior to enrollment, typically 
for many years, so the required two-week washout period free of 
antioxidant supplements prior to baseline oxidative stress 
measurements may have been inadequate for this population. 
While this washout period is likely to be sufficient for water- 
soluble antioxidants such as vitamin C, the fat-soluble 
antioxidants such as carotenoids or vitamin E have longer serum 
and tissue half-lives and may require considerably longer washout 
periods in future studies of oxidative stress in the elderly. Tn a 
previous study, changes in the placebo control group indicated 
the removal of antioxidant supplementation may lead to a gradual 
decrease in markers of oxidative status (Nelson et al., 2003).
A recent small study found clinically normal fellow eyes of 
patients with exudative AMD had lower levels of macular pigment, 
assessed by heterochromatic flicker photometry (Beatty et al., 
2001). Tn a larger study of macular carotenoid levels using 
resonance Raman spectroscopy, AMD patients were observed to 
have significantly lower levels of lutein and zeaxanthin relative to 
age-matched control eyes unless they had been consuming 
high-dose lutein supplements (> 4 mg/day) for long periods of 
time (Bernstein et al., 2002).
Tn this small study of limited duration, no statistically significant 
differences in macular pigment could be identified as a 
consequence of any of the interventions. This may be due in part 
to inherent limitations of all noninvasive measurement methods 
for macular pigment which typically have a day to day variability 
of approximately 10%. More invasive measurement methods 
such as HPI.C have less variability, but their spatial resolution is 
very limited. The overall conclusions of this study are that any
improvements in accuracy and reproducibility of the method for 
measuring macular pigment would be beneficial, any means of 
simplifying the measurements or improving patient competence 
would be constructive, and that the magnitude of the changes in 
macular pigment may need to be increased for the changes to be 
observable and significant. The former can be achieved by 
enhancing the operating characteristics of the device and 
improving the device-user interface, and the latter can be 
accomplished by either extending the duration of the study or 
increasing the daily levels of dietary supplementation.
The results from Table 5 suggest some guidelines. The global 
mean of the measured ocular density was approximately 0.3 OD 
units. Tn order to distinguish a 25 % change in the level of optical 
density (a change o f0.075 O D  units, or equivalently a change of 
25% in macular pigment to which the optical density is linearly 
related) the standard deviation of each of the groups would have 
to be smaller than 0.075 O D  units, for small groups with about 
15 individuals per group. This suggests that for discrimination 
of the effects of diet, it will be helpful to have groups with 
reasonably homogeneous initial levels of macular pigment, patients 
with the ability to generate mean readings for each eye with 
standard deviations less than about 0.075 OD and with bilateral 
symmetry such that the difference between mean values for each 
eye is no larger than this value. Within these guidelines, it is 
readily perceivable from Table 5 that the consistency of the 
measurements would need to be increased about three-fold. Other 
investigators also have been concerned about the importance of 
the protocol for measuring macular pigment, and a protocol for 
improving the accuracy of HFP measurements is available on the 
world-wide-web (Snodderly et al., 2004). Alternative methods 
for evaluating the level of macular pigment are emerging, and 
those that are rapid, do not involve pupil dilation, and are objective 
will offer improved opporamity for resolving the effects of dietary 
intervention and its value.
Whatever technique is utilized for measuring macular pigment, 
there will be numerous underlying assumptions and requirements 
for successful, reproducible, and accurate evaluation of macular 
pigment. For psychophysical methods, one assumption is that 
the relative retinal sensitivity to short and middle-wavelength 
lights is the same in foveal and parafoveal regions, an
Table 5. Mean Macular Pigment Density as Measured by Heterochromatic Flicker Photometry (HFP)
HFP Perceived Optical Density 
(Mean ± SD
Right Eye I.eft Eye
Pre- Post- Pre- Post-
Capsule (n = 9) 0.37 ± 0.20 0.41 ± 0.23 0.26 ± 0.19 0.37 ± 0.22
Tablet (n = 9) 0.50 ± 0.27 0.39 ± 0.26 0.32 ± 0.14 0.32 ± 0.18
Diet (n = 11) 0.24 ± 0.12 0.22 ± 0.18 0.32 ± 0.16 0.24 ± 0.16
Total (n = 29) 0.35 ± 0.21 0.34 ± 0.21 0.31 ± 0.21 0.31 ± 0.17
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approximation improved with proper adjustment of the flicker 
frequency (Snodderly et al., 1999). Eisner and colleagues have 
noted irregularities in cone distributions particularly in older 
subjects who had signs of retinal disease (Eisner et al., 1998), and 
the implications for accurate measurement of macular pigment 
are uncertain. A recent study has shown that psychophysical 
methods also may not provide accurate assessment of macular 
pigment either when the amount of pigment is at a low level 
(Delori et al., 2001) or when peripheral macular pigment levels 
are elevated, as may occur with supplementation (Bhosale and 
Bernstein, unpublished data). Furthermore, since the most 
important evaluations probably will be those made in the elderly, 
the effects of additional sources of scattering and absorption will 
need to be incorporated into any analysis.
Previous supplementation studies using subjective and objective 
measurement techniques have generally shown significant increases 
in macular carotenoid levels in response to higher dose lutein 
supplementation within three months, but these were always 
performed in a relatively young population, not in the elderly 
(Landrum et al.,1997; Berendschot et al., 2000; Hammond et 
al„ 1997). It is possible that the transport processes of carotenoids 
from the gut to the macula via liver and bloodstream are slower or 
less efficient in the elderly. Uptake of lutein and zeaxanthin into 
the macula is likely to be mediated by specific and saturable 
binding proteins (Yemelyanov, et al., 2001), which may decline 
with age. An isoform of human glutathione S-transferase (GSTP1) 
extracted from human macula membrane tissue has been 
demonstrated to bind zeaxanthin and may enhance the 
antioxidant function of zeaxanthin within the macula (Bhosale 
et al. 2003) Antioxidant efficiency within the macula may be a 
function of both the serum and macular level of lutein and 
zeaxanthin as well as the activity of the specific transfer proteins.
CONCLUSION
This 12-week pilot study demonstrates that supplementation 
with two different antioxidant formulations directed toward 
individuals potentially at risk for visual loss from AMD exhibited 
positive serum antioxidant responses. These serum antioxidant 
level and biomarkers of oxidative stress responses were of 
comparable magnitude to those observed with a dietary 
intervention enriched in fruits and vegetables containing high 
levels o f  carotenoids. Future  studies o f  caro tenoid  
supplementation in the elderly may require longer periods of 
supplementation and/or higher dosage levels to translate serum 
increases into clinically significant changes in macular carotenoid 
levels. Refinements in techniques for the measurement of macular 
pigment will be beneficial for detecting changes in carotenoid 
content of the macula. The results from the study reported here 
indicate the need for longer-term, continuous supplementation 
with antioxidants and xanthophylls to translate serum responses 
into ocular benefit.
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